1 Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas and Division of Nephrology and Hypertension, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas
2 Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota
National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder CKD-MBD. Available at https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed August 4, 2020
National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder CKD-MBD. Available at https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed August 4, 2020)| false
Seiler-MusslerS, LimbachAS, EmrichIE, PickeringJW, RothHJ, FliserD,
et al.
.: Association of nonoxidized parathyroid hormone with cardiovascular and kidney disease outcomes in chronic kidney disease. Clin J Am Soc Nephrol13: 569–576, 2018PubMed
Seiler-MusslerS, LimbachAS, EmrichIE, PickeringJW, RothHJ, FliserD, .: Association of nonoxidized parathyroid hormone with cardiovascular and kidney disease outcomes in chronic kidney disease. Clin J Am Soc Nephrol13: 569–576, 2018PubMed10.2215/CJN.06620617)| false
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA,
et al.
.: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD Treated by dialysis. Am J Kidney Dis67: 559–566, 2016PubMed
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA, .: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD Treated by dialysis. Am J Kidney Dis67: 559–566, 2016PubMed10.1053/j.ajkd.2015.06.023)| false
CovicA, VoroneanuL, ApetriiM: PTH and/or bone histology: Are we still waiting for a verdict from the CKD-MBD grand jury?Am J Kidney Dis67: 535–538, 2016PubMed
CovicA, VoroneanuL, ApetriiM: PTH and/or bone histology: Are we still waiting for a verdict from the CKD-MBD grand jury?Am J Kidney Dis67: 535–538, 2016PubMed10.1053/j.ajkd.2015.11.028)| false
BushinskyDA, ChertowGM, ChengS, DengH, KopytN, MartinKJ,
et al.
.: One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant35: 1769–1778, 2020PubMed
FloegeJ, TsirtsonisK, IlesJ, DruekeTB, ChertowGM, ParfreyP: Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int93: 1475–1482, 2018PubMed
FloegeJ, TsirtsonisK, IlesJ, DruekeTB, ChertowGM, ParfreyP: Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int93: 1475–1482, 2018PubMed10.1016/j.kint.2017.12.014)| false
FukagawaM, ShimazakiR, AkizawaT; Evocalcet study group: Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int94: 818–825, 2018PubMed
FukagawaM, ShimazakiR, AkizawaT; Evocalcet study group: Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int94: 818–825, 2018PubMed10.1016/j.kint.2018.05.013)| false
MazzaferroS, PasqualiM: Direct bone effects of calcimimetics in chronic kidney disease?Kidney Int95: 1012–1014, 2019PubMed10.1016/j.kint.2019.01.045)| false
RudermanI, HoltSG, KirklandGS, MaslenS, HawleyCM, OliverV,
et al.
.: Outcomes of cinacalcet withdrawal in Australian dialysis patients. Intern Med J49: 48–54, 2019PubMed
ThadhaniRI, RosenS, OfsthunNJ, UsvyatLA, DalrympleLS, MadduxFW,
et al.
.: Conversion from intravenous vitamin D analogs to oral calcitriol in patients receiving maintenance hemodialysis. Clin J Am Soc Nephrol15: 384–391, 2020PubMed
PiresGO, VieiraIO, HernandesFR, TeixeiraAL, OliveiraIB, DominguezWV,
et al.
.: Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. Bone121: 277–283, 2019PubMed
PiresGO, VieiraIO, HernandesFR, TeixeiraAL, OliveiraIB, DominguezWV, .: Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. Bone121: 277–283, 2019PubMed10.1016/j.bone.2019.01.029)| false
FangL, WuJ, LuoJ, WenP, XiongM, CaoJ,
et al.
.: Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism. BMC Nephrol19: 142, 2018PubMed
FangL, WuJ, LuoJ, WenP, XiongM, CaoJ, .: Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism. BMC Nephrol19: 142, 2018PubMed10.1186/s12882-018-0934-1)| false
El-HusseiniA, WangK, EdonA, SaxonD, LimaF, SloanD,
et al.
.: Value of intraoperative parathyroid hormone assay during parathyroidectomy in dialysis and renal transplant patients with secondary and tertiary hyperparathyroidism. Nephron138: 119–128, 2018PubMed
El-HusseiniA, WangK, EdonA, SaxonD, LimaF, SloanD, .: Value of intraoperative parathyroid hormone assay during parathyroidectomy in dialysis and renal transplant patients with secondary and tertiary hyperparathyroidism. Nephron138: 119–128, 2018PubMed10.1159/000482016)| false
van der PlasWY, EngelsmanAF, UmakanthanM, MatherA, SidhuSB, DelbridgeLW,
et al.
.: Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics. Surgery165: 135–141, 2019PubMed
van der PlasWY, EngelsmanAF, UmakanthanM, MatherA, SidhuSB, DelbridgeLW, .: Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics. Surgery165: 135–141, 2019PubMed10.1016/j.surg.2018.04.092)| false
LeeJD, KuoEJ, DuL, YehMW, LivhitsMJ: Risk factors for readmission after parathyroidectomy for renal hyperparathyroidism. World J Surg43: 534–539, 2019PubMed
LeeJD, KuoEJ, DuL, YehMW, LivhitsMJ: Risk factors for readmission after parathyroidectomy for renal hyperparathyroidism. World J Surg43: 534–539, 2019PubMed10.1007/s00268-018-4823-3)| false
FerrandinoR, RoofS, MaY, ChanL, PoojaryP, SahaA,
et al.
.: Unplanned 30-Day readmissions after parathyroidectomy in patients with chronic kidney disease: A nationwide analysis. Otolaryngol Head Neck Surg157: 955–965, 2017PubMed
FerrandinoR, RoofS, MaY, ChanL, PoojaryP, SahaA, .: Unplanned 30-Day readmissions after parathyroidectomy in patients with chronic kidney disease: A nationwide analysis. Otolaryngol Head Neck Surg157: 955–965, 2017PubMed10.1177/0194599817721154)| false
AndersonKJr, RuelE, AdamMA, ThomasS, YoungwirthL, StangMT,
et al.
.: Subtotal vs. total parathyroidectomy with autotransplantation for patients with renal hyperparathyroidism have similar outcomes. Am J Surg214: 914–919, 2017PubMed
AndersonKJr, RuelE, AdamMA, ThomasS, YoungwirthL, StangMT, .: Subtotal vs. total parathyroidectomy with autotransplantation for patients with renal hyperparathyroidism have similar outcomes. Am J Surg214: 914–919, 2017PubMed10.1016/j.amjsurg.2017.07.018)| false
IsakssonE, IvarssonK, AkaberiS, MuthA, PrützKG, ClyneN,
et al.
.: Total versus subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery165: 142–150, 2019PubMed
van der PlasWY, DulferRR, EngelsmanAF, VogtL, de BorstMH, van GinhovenTM,
et al.
.; Dutch Hyperparathryoid Study Group (DHSG): Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transplant32: 1902–1908, 2017PubMed
van der PlasWY, DulferRR, EngelsmanAF, VogtL, de BorstMH, van GinhovenTM, .; Dutch Hyperparathryoid Study Group (DHSG): Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transplant32: 1902–1908, 2017PubMed10.1093/ndt/gfx044)| false
IshaniA, LiuJ, WetmoreJB, LoweKA, DoT, BradburyBD,
et al.
.: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol10: 90–97, 2015PubMed
IshaniA, LiuJ, WetmoreJB, LoweKA, DoT, BradburyBD, .: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol10: 90–97, 2015PubMed10.2215/CJN.03520414)| false
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL,
et al.
.: Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med168: 422–430, 2018PubMed
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL, .: Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med168: 422–430, 2018PubMed10.7326/M17-2640)| false
GauciC, MoranneO, FouquerayB, de la FailleR, MaruaniG, HaymannJP,
et al.
.; NephroTest Study Group: Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol19: 1592–1598, 2008PubMed
GauciC, MoranneO, FouquerayB, de la FailleR, MaruaniG, HaymannJP, .; NephroTest Study Group: Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol19: 1592–1598, 2008PubMed10.1681/ASN.2007040449)| false
EvenepoelP, BammensB, ClaesK, KuypersD, MeijersBK, VanrenterghemY: Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol5: 2085–2092, 2010PubMed
EvenepoelP, BammensB, ClaesK, KuypersD, MeijersBK, VanrenterghemY: Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol5: 2085–2092, 2010PubMed10.2215/CJN.02460310)| false
AlbrightF, BauerW, ClaflinD, CockrillJR; The Effect of Phosphate Ingestion in Clinical Hyperparathyroidism: Studies in parathyroid physiology: III. J Clin Invest11: 411–435, 1932PubMed
AlbrightF, BauerW, ClaflinD, CockrillJR; The Effect of Phosphate Ingestion in Clinical Hyperparathyroidism: Studies in parathyroid physiology: III. J Clin Invest11: 411–435, 1932PubMed10.1172/JCI100423)| false
AlmadenY, CanalejoA, HernandezA, BallesterosE, Garcia-NavarroS, TorresA,
et al.
.: Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res11: 970–976, 1996PubMed
AlmadenY, CanalejoA, HernandezA, BallesterosE, Garcia-NavarroS, TorresA, .: Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res11: 970–976, 1996PubMed10.1002/jbmr.5650110714)| false
PortaleAA, HalloranBP, MorrisRCJr: Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest80: 1147–1154, 1987PubMed
PortaleAA, HalloranBP, MorrisRCJr: Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest80: 1147–1154, 1987PubMed10.1172/JCI113172)| false
IxJH, AndersonCA, SmitsG, PerskyMS, BlockGA: Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study. Am J Clin Nutr100: 1392–1397, 2014PubMed
IxJH, AndersonCA, SmitsG, PerskyMS, BlockGA: Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study. Am J Clin Nutr100: 1392–1397, 2014PubMed10.3945/ajcn.114.085498)| false
LeonJB, SullivanCM, SehgalAR. The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores. J. Ren. Nutr.23: 265–270.e262, 2013
LeonJB, SullivanCM, SehgalAR. The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores. J. Ren. Nutr. 23: 265–270.e262, 201310.1053/j.jrn.2012.12.003)| false
McCutcheonJ, CampbellK, FergusonM, DayS, RossiM: Prevalence of phosphorus-based additives in the Australian food supply: A challenge for dietary education?J Ren Nutr25: 440–444, 2015PubMed
McCutcheonJ, CampbellK, FergusonM, DayS, RossiM: Prevalence of phosphorus-based additives in the Australian food supply: A challenge for dietary education?J Ren Nutr25: 440–444, 2015PubMed10.1053/j.jrn.2015.04.003)| false
CalvoMS, MoshfeghAJ, TuckerKL: Assessing the health impact of phosphorus in the food supply: Issues and considerations. Adv Nutr5: 104–113, 2014PubMed10.3945/an.113.004861)| false
VervloetMG, SezerS, MassyZA, JohanssonL, CozzolinoM, FouqueD; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group: The role of phosphate in kidney disease. Nat Rev Nephrol13: 27–38, 2017PubMed
VervloetMG, SezerS, MassyZA, JohanssonL, CozzolinoM, FouqueD; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group: The role of phosphate in kidney disease. Nat Rev Nephrol13: 27–38, 2017PubMed10.1038/nrneph.2016.164)| false
CalvoMS, ShermanRA, UribarriJ: Dietary phosphate and the forgotten kidney patient: A critical need for FDA regulatory action. Am J Kidney Dis73: 542–551, 2019PubMed
CalvoMS, ShermanRA, UribarriJ: Dietary phosphate and the forgotten kidney patient: A critical need for FDA regulatory action. Am J Kidney Dis73: 542–551, 2019PubMed10.1053/j.ajkd.2018.11.004)| false
SullivanC, SayreSS, LeonJB, MachekanoR, LoveTE, PorterD,
et al.
.: Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA301: 629–635, 2009PubMed
de FornasariML, Dos Santos SensYA: Replacing phosphorus-containing food additives with foods without additives reduces phosphatemia in end-stage renal disease patients: A randomized clinical trial. J Ren Nutr27: 97–105, 2017PubMed
de FornasariML, Dos Santos SensYA: Replacing phosphorus-containing food additives with foods without additives reduces phosphatemia in end-stage renal disease patients: A randomized clinical trial. J Ren Nutr27: 97–105, 2017PubMed10.1053/j.jrn.2016.08.009)| false
D’AlessandroC, PiccoliGB, CupistiA: The “phosphorus pyramid”: A visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol16: 9, 2015PubMed
D’AlessandroC, PiccoliGB, CupistiA: The “phosphorus pyramid”: A visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol16: 9, 2015PubMed10.1186/1471-2369-16-9)| false
ManleyHJ, GarvinCG, DrayerDK, ReidGM, BenderWL, NeufeldTK,
et al.
.: Medication prescribing patterns in ambulatory haemodialysis patients: Comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant19: 1842–1848, 2004PubMed
ChiuYW, TeitelbaumI, MisraM, de LeonEM, AdzizeT, MehrotraR: Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol4: 1089–1096, 2009PubMed
ChiuYW, TeitelbaumI, MisraM, de LeonEM, AdzizeT, MehrotraR: Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol4: 1089–1096, 2009PubMed10.2215/CJN.00290109)| false
LiJ, WangL, HanM, XiongY, LiaoR, LiY,
et al.
.: The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease. Nutr Diabetes9: 14, 2019PubMed
LiJ, WangL, HanM, XiongY, LiaoR, LiY, .: The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease. Nutr Diabetes9: 14, 2019PubMed10.1038/s41387-019-0080-2)| false
ShermanRA, RavellaS, KapoianT: A dearth of data: the problem of phosphorus in prescription medications. Kidney Int87: 1097–1099, 2015PubMed10.1038/ki.2015.67)| false
ShermanRA, RavellaS, KapoianT: The phosphate content of prescription medication: A new consideration. Ther Innov Regul Sci49: 886–889, 2015PubMed10.1177/2168479015592194)| false
NelsonSM, SarabiaSR, ChristilawE, WardEC, LynchSK, AdamsMA,
et al.
.: Phosphate-containing prescription medications contribute to the daily phosphate intake in a third of hemodialysis patients. J Ren Nutr27: 91–96, 2017PubMed
NelsonSM, SarabiaSR, ChristilawE, WardEC, LynchSK, AdamsMA, .: Phosphate-containing prescription medications contribute to the daily phosphate intake in a third of hemodialysis patients. J Ren Nutr27: 91–96, 2017PubMed10.1053/j.jrn.2016.09.007)| false
WinkelmayerWC, ChertowGM: Off-label use of phosphate binders in non-dialysis-dependent CKD. Am J Kidney Dis56: 813–816, 2010PubMed10.1053/j.ajkd.2010.09.004)| false
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL,
et al.
.: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What’s changed and why it matters. Kidney Int92: 26–36, 2017PubMed
Di IorioB, BellasiA, RussoD; INDEPENDENT Study Investigators: Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin J Am Soc Nephrol7: 487–493, 2012PubMed
Di IorioB, BellasiA, RussoD; INDEPENDENT Study Investigators: Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin J Am Soc Nephrol7: 487–493, 2012PubMed10.2215/CJN.03820411)| false
ChertowGM, BurkeSK, RaggiP; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int62: 245–252, 2002PubMed
ChertowGM, BurkeSK, RaggiP; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int62: 245–252, 2002PubMed10.1046/j.1523-1755.2002.00434.x)| false
BlockGA, SpiegelDM, EhrlichJ, MehtaR, LindberghJ, DreisbachA,
et al.
.: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int68: 1815–1824, 2005PubMed
BlockGA, SpiegelDM, EhrlichJ, MehtaR, LindberghJ, DreisbachA, .: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int68: 1815–1824, 2005PubMed10.1111/j.1523-1755.2005.00600.x)| false
InabaM, OkunoS, NagayamaH, YamadaS, IshimuraE, ImanishiY,
et al.
.: Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone. J Ren Nutr25: 242–246, 2015PubMed
InabaM, OkunoS, NagayamaH, YamadaS, IshimuraE, ImanishiY, .: Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone. J Ren Nutr25: 242–246, 2015PubMed10.1053/j.jrn.2014.10.013)| false
MallucheHH, SiamiGA, SwanepoelC, WangGH, MawadH, ConferS,
et al.
.; SPD405-307 Lanthanum Carbonate Study Group: Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol70: 284–295, 2008PubMed
MallucheHH, SiamiGA, SwanepoelC, WangGH, MawadH, ConferS, .; SPD405-307 Lanthanum Carbonate Study Group: Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol70: 284–295, 2008PubMed)| false
St PeterWL, WaznyLD, WeinhandlED: Phosphate-binder use in US dialysis patients: Prevalence, costs, evidence, and policies. Am J Kidney Dis71: 246–253, 2018PubMed
St PeterWL, WaznyLD, WeinhandlED: Phosphate-binder use in US dialysis patients: Prevalence, costs, evidence, and policies. Am J Kidney Dis71: 246–253, 2018PubMed10.1053/j.ajkd.2017.09.007)| false
ZhangC, WenJ, LiZ, FanJ: Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: A systematic review. BMC Nephrol14: 226, 2013PubMed
ZhangC, WenJ, LiZ, FanJ: Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: A systematic review. BMC Nephrol14: 226, 2013PubMed10.1186/1471-2369-14-226)| false
EtoN, MiyataY, OhnoH, YamashitaT: Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant20: 1378–1384, 2005PubMed
EtoN, MiyataY, OhnoH, YamashitaT: Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant20: 1378–1384, 2005PubMed10.1093/ndt/gfh781)| false
LiuXY, YaoJR, XuR, XuLX, ZhangYF, LuS,
et al.
.: Investigation of nicotinamide as more than an anti-phosphorus drug in chronic hemodialysis patients: A single-center, double-blind, randomized, placebo-controlled trial. Ann Transl Med8: 530, 2020PubMed
LiuXY, YaoJR, XuR, XuLX, ZhangYF, LuS, .: Investigation of nicotinamide as more than an anti-phosphorus drug in chronic hemodialysis patients: A single-center, double-blind, randomized, placebo-controlled trial. Ann Transl Med8: 530, 2020PubMed10.21037/atm.2020.03.228)| false
MalhotraR, KatzR, HoofnagleA, BostomA, RifkinDE, McbrideR,
et al.
.: The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol13: 36–44, 2018PubMed
MalhotraR, KatzR, HoofnagleA, BostomA, RifkinDE, McbrideR, .: The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol13: 36–44, 2018PubMed10.2215/CJN.05440517)| false
IxJH, IsakovaT, LariveB, RaphaelKL, RajDS, CheungAK,
et al.
.: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE trial. J Am Soc Nephrol30: 1096–1108, 2019PubMed
IxJH, IsakovaT, LariveB, RaphaelKL, RajDS, CheungAK, .: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE trial. J Am Soc Nephrol30: 1096–1108, 2019PubMed10.1681/ASN.2018101058)| false
BlockGA, RosenbaumDP, YanA, ChertowGM: Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial. J Am Soc Nephrol30: 641–652, 2019PubMed
BlockGA, RosenbaumDP, YanA, ChertowGM: Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial. J Am Soc Nephrol30: 641–652, 2019PubMed10.1681/ASN.2018080832)| false
JanszTT, ÖzyilmazA, GrootemanMPC, HoekstraT, RomijnM, BlankestijnPJ,
et al.
.: Long-term clinical parameters after switching to nocturnal haemodialysis: A Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration. BMJ Open8: e019900, 2018PubMed
JanszTT, ÖzyilmazA, GrootemanMPC, HoekstraT, RomijnM, BlankestijnPJ, .: Long-term clinical parameters after switching to nocturnal haemodialysis: A Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration. BMJ Open8: e019900, 2018PubMed10.1136/bmjopen-2017-019900)| false
WongB, CollisterD, MuneerM, StorieD, CourtneyM, LloydA,
et al.
.: In-center nocturnal hemodialysis versus conventional hemodialysis: A systematic review of the evidence. Am J Kidney Dis70: 218–234, 2017PubMed
KongX, ZhangL, ZhangL, ChenN, GuY, YuX,
et al.
.: Mineral and bone disorder in Chinese dialysis patients: A multicenter study. BMC Nephrol13: 116, 2012PubMed
KongX, ZhangL, ZhangL, ChenN, GuY, YuX, .: Mineral and bone disorder in Chinese dialysis patients: A multicenter study. BMC Nephrol13: 116, 2012PubMed10.1186/1471-2369-13-116)| false
PagéDE, KnollGA, CheungV: The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients. Adv Perit Dial18: 189–191, 2002PubMed
PagéDE, KnollGA, CheungV: The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients. Adv Perit Dial18: 189–191, 2002PubMed)| false
